Johnson & Johnson (JNJ, $138.03) shares plummet as $29 million lawsuit looms
With more than 13,000 existing lawsuits open, the most recent for New Jersey-based Johnson & Johnson is an accusation by a woman alleging asbestos in the company’s talcum products has caused her cancer. A California jury in Oakland has found the company guilty and has ordered it to pay $29 million to the victim.
The company, on the other hand, has denied such allegations claiming that its products are checked by experts and numerous studies and tests have already proved that their products are free from any cancer causing substance. The company will now appeal the verdict.
This is not the first of its kind. J&J has a long history of such allegations. A Los Angeles jury last year awarded $21.7 million to a woman who blamed her cancer on the powder. The company has lost a motion to appeal a verdict in Missouri that awarded more than $4 billion to 22 women who accused that the asbestos in the company’s talcum products is the reason for their ovarian cancer.
Following the current lawsuit, shares of the company have fallen sharply. Last summer, in a move to break away from its declining market share, the company launched its iconic baby product line. But the 124 year old company has fallen out of customer preferences that now have turned to cleaner, natural products from trendy upstart brands.
The company saw its shares climb just 8% since the beginning of 2019 and just 4% in past 12 months to clock a market cap of $371.3 billion.
JNJ in +0.66% Uptrend, growing for three consecutive days on October 16, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JNJ advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on JNJ as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on September 29, 2025. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
JNJ broke above its upper Bollinger Band on September 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on September 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.896) is normal, around the industry mean (9.951). P/E Ratio (18.562) is within average values for comparable stocks, (24.525). Projected Growth (PEG Ratio) (1.038) is also within normal values, averaging (2.064). Dividend Yield (0.026) settles around the average of (0.028) among similar stocks. P/S Ratio (5.058) is also within normal values, averaging (3.575).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement